AcquisitionsMay 19, 2026, 08:32 AM
Nexalin Acquires PONM for $1.3M; Secures Digital Health Platform
AI Summary
Nexalin Technology, Inc. announced the closing of its acquisition of PONM, Inc. for $1.3 million, payable in Nexalin common stock. This acquisition grants Nexalin ownership of PONM's digital health platform and an exclusive license to its proprietary software, which supports the HALO™ Clarity program and Nexalin NeuroCare™ virtual clinic. The platform is crucial for Nexalin's planned FDA pivotal trial for moderate-to-severe insomnia, expected to begin in Q2 2026, and enhances control over its digital infrastructure. Additionally, GreenLight Ventures, the seller, has become a significant equity holder in Nexalin and entered into a strategic partnership to provide ongoing support.
Key Highlights
- Nexalin Technology completed the acquisition of PONM, Inc. for $1.3 million.
- Consideration for the acquisition is payable in Nexalin common stock in tranches.
- Nexalin secured an exclusive license to PONM's proprietary digital health software features.
- PONM's platform supports Nexalin's HALO™ Clarity program and NeuroCare™ virtual clinic.
- The technology is deployed at UCSD, supporting a TBI/PTSD study and future trials.
- GreenLight Ventures, the seller, became a meaningful equity holder in Nexalin.
- A strategic partnership with GreenLight provides Nexalin access to product and regulatory capabilities.
- The platform will support a planned 160-participant FDA pivotal trial for insomnia in Q2 2026.
Price Impact
More from NXL